Switch to:

Intra-Cellular Therapies EBIT

: $-211.66 Mil (TTM As of Sep. 2020)
View and export this data going back to 2013. Start your Free Trial

Intra-Cellular Therapies's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2020 was $-55.94 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2020 was $-211.66 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Intra-Cellular Therapies's annualized ROC % for the quarter that ended in Sep. 2020 was -549.43%. Intra-Cellular Therapies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2020 was -920.51%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Intra-Cellular Therapies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2020 was -16.16%.


Intra-Cellular Therapies EBIT Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Intra-Cellular Therapies Annual Data
Dec12 Mar13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
EBIT Premium Member Only Premium Member Only Premium Member Only -104.79 -115.32 -102.84 -162.27 -154.01

Intra-Cellular Therapies Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.38 -41.77 -49.09 -64.87 -55.94

Intra-Cellular Therapies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2020 was -41.769 (Dec. 2019 ) + -49.086 (Mar. 2020 ) + -64.872 (Jun. 2020 ) + -55.936 (Sep. 2020 ) = $-211.66 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Intra-Cellular Therapies  (NAS:ITCI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Intra-Cellular Therapies's annualized ROC % for the quarter that ended in Sep. 2020 is calculated as:

ROC % (Q: Sep. 2020 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2020 ) + Invested Capital (Q: Sep. 2020 ))/ count )
=-223.744 * ( 1 - 0% )/( (37.745 + 43.701)/ 2 )
=-223.744/40.723
=-549.43 %

where

Invested Capital(Q: Jun. 2020 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=440.931 - 24.856 - ( 407.759 - max(0, 40.243 - 418.573+407.759))
=37.745

Invested Capital(Q: Sep. 2020 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=771.294 - 20.756 - ( 721.947 - max(0, 38.029 - 744.866+721.947))
=43.701

Note: The Operating Income data used here is four times the quarterly (Sep. 2020) data.

2. Joel Greenblatt's definition of Return on Capital:

Intra-Cellular Therapies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2020 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2020 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2020  Q: Sep. 2020
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-223.744/( ( (22.271 + max(-25.455, 0)) + (26.342 + max(-9.843, 0)) )/ 2 )
=-223.744/( ( 22.271 + 26.342 )/ 2 )
=-223.744/24.3065
=-920.51 %

where Working Capital is:

Working Capital(Q: Jun. 2020 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.353 + 2.335 + 6.126) - (24.856 + 0 + 11.413)
=-25.455

Working Capital(Q: Sep. 2020 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(7.481 + 2.947 + 12.491) - (20.756 + 0 + 12.006)
=-9.843

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2020) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Intra-Cellular Therapies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2020 )
=-211.663/1309.540
=-16.16 %

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Intra-Cellular Therapies EBIT Related Terms


Intra-Cellular Therapies EBIT Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)